查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611190

全球女性健康市場規模、佔有率和趨勢分析報告：按應用、藥物類別、年齡、地區和細分市場預測（2025-2030）

Women's Health Market Size, Share & Trends Analysis Report By Application (Contraceptives, Menopause), By Drug Class (Hormonal Therapies, Pain And Symptom Management), By Age (50 Years And Above), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

女性健康市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年全球女性健康市場規模將達到685.3億美元，2025年至2030年複合年成長率為5.1%。

創新的新產品推出和女性健康領域強大的產品線是推動市場成長的關鍵因素。例如，2021 年 5 月，食品藥物管理局核准了輝瑞與 Myovant Sciences 共同開發的 Myfenbrey，用於治療與月經出血過多相關的子宮肌瘤。子宮內膜異位症盛行率的增加和非營利組織的支持的增加預計將在預測期內推動市場成長。

例如，比爾及梅琳達蓋茲基金會已承諾從 2021 年至 2030 年每年提供 2.8 億美元，用於支持新避孕技術和計劃生育舉措的開發。根據世界衛生組織 2021 年報告，全球約 10%（1.9 億人）的育齡女孩和婦女受到子宮內膜異位症的影響。子宮內膜異位症是一種慢性疾病，會導致經痛、排便疼痛、腹脹、噁心和疲勞。 COVID-19 大流行對市場產生了負面影響。各國政府為遏制 SARS-CoV-2 傳播而採取的嚴格措施，例如社交距離措施和全部區域的封鎖，對治療設施和婦科診所產生了負面影響。

例如，低收入和中等收入國家長效和短效可逆避孕藥的使用率下降。主要企業在產品開發和商業化方面的聯合研究、協議和聯盟等策略性舉措預計將推動市場成長。例如，2021年10月，Richter和Hikma簽訂了一項獨家授權合約，在美國商業化地Denosumab，該藥物構成Xgeva和Prolia的生物相似藥。此外，學名藥競爭的加劇預計將在專利到期後增加價格壓力並抑制市場成長。

例如，2020年至2021年，Forteo專利到期後銷售額下降了23%。由於優惠的報銷政策、主要市場參與者的存在、支持性的政府法規、產品核准和商業化以及女性避孕器具的高使用率，2021 年全球市場將由北美主導。由於政府在婦女健康方面的支出增加，預計亞太地區在預測期內將以最快的複合年成長率成長。例如，澳洲政府宣布投資 3.33 億美元支持衛生服務和支援。

女性健康市場報告亮點

  • 受計劃生育意識不斷提高和避孕方法技術不斷進步的推動，避孕藥具領域的收益佔有率最高，到 2024 年將佔全球收益的 35.07% 以上。
  • 荷爾蒙療法領域預計將在 2024 年引領市場，並在預測期內實現最快的成長速度。
  • 其他（50 歲以下）細分市場預計將在 2024 年佔據市場主導地位，並在預測期內保持其地位。 50歲以下的女性更容易面臨與不孕症相關的問題，例如子宮內膜異位症、荷爾蒙性不孕症和多囊性卵巢症候群。
  • 北美女性健康市場在2024年以43.04%的佔有率主導全球市場。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章 女性健康市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 女性健康市場分析工具
    • 產業分析：波特五力分析
    • PESTEL分析
    • 價格分析

第4章 女性保健品市場：使用量估算及趨勢分析

  • 應用市場佔有率（2024/2030）
  • 細分儀表板
  • 全球女性健康市場：應用前景
  • 2018-2030年市場規模、預測及趨勢分析
    • 荷爾蒙不孕症
    • 避孕藥
    • 停經後骨質疏鬆症
    • 子宮內膜異位症和子宮肌瘤
    • 閉經
    • 卵巢症候群（PCOS）

第5章 女性保健市場：藥品類別估算與趨勢分析

  • 藥品類市場佔有率（2024/2030）
  • 細分儀表板
  • 全球女性健康市場：藥品類別展望
  • 2018-2030年市場規模、預測及趨勢分析
    • 荷爾蒙療法
    • 骨骼健康促進劑
    • 不孕症藥物
    • 促性腺激素釋放激素調變器
    • 疼痛和症狀管理
    • 代謝劑
    • 其他

第6章 女性健康市場：年齡估算及趨勢分析

  • 依年齡分類的市場佔有率(2024/2030)
  • 細分儀表板
  • 全球女性健康市場：年齡視角
  • 2018-2030年市場規模、預測及趨勢分析
    • 50歲以上
    • 其他

第7章 女性健康市場：區域估計與趨勢分析

  • 區域市場佔有率分析（2024/2030）
  • 區域市場儀表板
  • 全球區域市場概況
  • 市場規模及預測趨勢分析（2018-2030）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 主要企業市場佔有率分析：2024年
    • AbbVie, Inc.
    • Bayer AG
    • Merck &Co., Inc.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Agile Therapeutics
    • Amgen, Inc.
    • Apothecus Pharmaceutical Corp.
    • Blairex Laboratories, Inc.
    • Ferring BV
Product Code: GVR-1-68038-634-9

Women's Health Market Growth & Trends:

The global women's health market size is expected to reach USD 68.53 billion by 2030, registering a CAGR of 5.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The introduction of innovative novel products and the presence of a strong pipeline of women's health products are prime factors driving the market growth. For instance, in May 2021, the Food & Drug Administration approved Myfembree, developed by Pfizer Inc. in collaboration with Myovant Sciences, for uterine fibroids associated with heavy menstrual bleeding. An increase in the incidence of endometriosis and a rise in support from non-profit organizations are expected to fuel the market growth over the forecast period.

For instance, the Bill & Melinda Gates Foundation pledged USD 280 million every year from 2021 to 2030 for the development of new contraceptive technologies and to support family planning initiatives. According to the WHO report 2021, globally, around 10% (190 million) of reproductive-age girls and women are affected by endometriosis. It is a chronic disease related to severe pain during periods, bowel movements and/or urination, abdominal bloating, nausea, fatigue, etc. The COVID-19 pandemic had a negative impact on the market. Strict measures undertaken by governments to control the spread of the SARS-CoV-2, such as social distancing and community-wide lockdowns, have had a detrimental impact on treatment facilities & gynecological clinics.

For instance, in low- and middle-income countries there has been a decline in the usage of long- and short-acting reversible contraceptives. Strategic initiatives undertaken by key players, such as collaborations, agreements, and partnerships, for the development and commercialization of products are anticipated to drive market growth. For instance, in October 2021, Richter and Hikma signed an exclusive licensing agreement to commercialize denosumab, comprising biosimilar of Xgeva and Prolia in the U.S. Moreover, the growing competition from generic drugs increases the pricing pressure after patent expiration, which is anticipated to impede market growth.

For instance, after the patent expiry, the revenue of Forteo declined by 23% between 2020 and 2021. North America dominated the global market in 2021 owing to favorable reimbursement policies, the presence of key market players, supportive government regulations, approval & commercialization of products, and high usage of contraceptives among women. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period due to rising government spending on women's health. For instance, the Australian Government announced an investment of USD 333 million to support health services and support.

Women's Health Market Report Highlights:

  • The contraceptives segment held the highest revenue share of more than 35.07% of the global revenue in 2024, spurred by rising awareness of family planning and ongoing technological advancements in contraceptive methods.
  • Hormonal therapies segment led the market in 2024 and is expected to grow at fastest growth rate over the forecast period.
  • The others (below 50 years) segment dominated the market in 2024 and is expected to sustain the position for the forecast period. Women aged below 50 years are more likely to face issues associated with fertility, such as endometriosis, hormonal infertility, and polycystic ovary syndrome.
  • The North America women's health market dominated the global market with a share of 43.04% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Age
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. Drug class outlook
    • 2.2.3. Age outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Women's Health Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of target diseases
      • 3.2.1.2. Increasing initiatives by government and various organizations
      • 3.2.1.3. Rising publicly funded family planning services
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiry of major drugs
      • 3.2.2.2. Lawsuits related to products
      • 3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices
  • 3.3. Women's Health Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. Women's Health Market: Application Estimates & Trend Analysis

  • 4.1. Application Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Women's Health Market by Application Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Hormonal infertility
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Contraceptives
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Postmenopausal osteoporosis
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Endometriosis & uterine fibroids
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Menopause
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Polycystic ovary syndrome (PCOS)
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Women's Health Market: Drug Class Estimates & Trend Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Women's Health Market by Drug Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hormonal Therapies
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Bone Health Agents
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Fertility Agents
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. GnRH Modulators
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Pain and Symptom Management
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Metabolic Agents
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. Others
      • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Women's Health Market: Age Estimates & Trend Analysis

  • 6.1. Age Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Women's Health Market by Age Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. 50 years and above
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2. Postmenopausal osteoporosis
        • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3. Endometriosis & uterine fibroids
        • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.4. Menopause
        • 6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.5. Others
        • 6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Others
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Women's Health Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. AbbVie, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Bayer AG
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Merck & Co., Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Pfizer, Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Teva Pharmaceutical Industries Ltd.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Agile Therapeutics
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Amgen, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Apothecus Pharmaceutical Corp.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Blairex Laboratories, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Ferring B.V.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America women's health market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America women's health market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 North America women's health market, by age, 2018 - 2030 (USD Million)
  • Table 6 U.S. women's health market, by application, 2018 - 2030 (USD Million)
  • Table 7 U.S. women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 U.S. women's health market, by age, 2018 - 2030 (USD Million)
  • Table 9 Canada women's health market, by application, 2018 - 2030 (USD Million)
  • Table 10 Canada women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Canada women's health market, by age, 2018 - 2030 (USD Million)
  • Table 12 Mexico women's health market, by application, 2018 - 2030 (USD Million)
  • Table 13 Mexico women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Mexico women's health market, by age, 2018 - 2030 (USD Million)
  • Table 15 Europe women's health market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe women's health market, by application, 2018 - 2030 (USD Million)
  • Table 17 Europe women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Europe women's health market, by age, 2018 - 2030 (USD Million)
  • Table 19 Germany women's health market, by application, 2018 - 2030 (USD Million)
  • Table 20 Germany women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Germany women's health market, by age, 2018 - 2030 (USD Million)
  • Table 22 UK women's health market, by application, 2018 - 2030 (USD Million)
  • Table 23 UK women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 UK women's health market, by age, 2018 - 2030 (USD Million)
  • Table 25 France women's health market, by application, 2018 - 2030 (USD Million)
  • Table 26 France women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 France women's health market, by age, 2018 - 2030 (USD Million)
  • Table 28 Italy women's health market, by application, 2018 - 2030 (USD Million)
  • Table 29 Italy women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Italy women's health market, by age, 2018 - 2030 (USD Million)
  • Table 31 Spain women's health market, by application, 2018 - 2030 (USD Million)
  • Table 32 Spain women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Spain women's health market, by age, 2018 - 2030 (USD Million)
  • Table 34 Denmark women's health market, by application, 2018 - 2030 (USD Million)
  • Table 35 Denmark women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 Denmark women's health market, by age, 2018 - 2030 (USD Million)
  • Table 37 Sweden women's health market, by application, 2018 - 2030 (USD Million)
  • Table 38 Sweden women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 39 Sweden women's health market, by age, 2018 - 2030 (USD Million)
  • Table 40 Norway women's health market, by application, 2018 - 2030 (USD Million)
  • Table 41 Norway women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Norway women's health market, by age, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific women's health market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific women's health market, by application, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific women's health market, by age, 2018 - 2030 (USD Million)
  • Table 47 China women's health market, by application, 2018 - 2030 (USD Million)
  • Table 48 China women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 49 China women's health market, by age, 2018 - 2030 (USD Million)
  • Table 50 Japan women's health market, by application, 2018 - 2030 (USD Million)
  • Table 51 Japan women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 52 Japan women's health market, by age, 2018 - 2030 (USD Million)
  • Table 53 India women's health market, by application, 2018 - 2030 (USD Million)
  • Table 54 India women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 India women's health market, by age, 2018 - 2030 (USD Million)
  • Table 56 South Korea women's health market, by application, 2018 - 2030 (USD Million)
  • Table 57 South Korea women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 South Korea women's health market, by age, 2018 - 2030 (USD Million)
  • Table 59 Australia women's health market, by application, 2018 - 2030 (USD Million)
  • Table 60 Australia women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 61 Australia women's health market, by age, 2018 - 2030 (USD Million)
  • Table 62 Thailand women's health market, by application, 2018 - 2030 (USD Million)
  • Table 63 Thailand women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 Thailand women's health market, by age, 2018 - 2030 (USD Million)
  • Table 65 Latin America women's health market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America women's health market, by age, 2018 - 2030 (USD Million)
  • Table 67 Latin America women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 68 Latin America women's health market, by application, 2018 - 2030 (USD Million)
  • Table 69 Brazil women's health market, by application, 2018 - 2030 (USD Million)
  • Table 70 Brazil women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 71 Brazil women's health market, by age, 2018 - 2030 (USD Million)
  • Table 72 Argentina women's health market, by application, 2018 - 2030 (USD Million)
  • Table 73 Argentina women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 74 Argentina women's health market, by age, 2018 - 2030 (USD Million)
  • Table 75 MEA women's health market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA women's health market, by application, 2018 - 2030 (USD Million)
  • Table 77 MEA women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 78 MEA women's health market, by age, 2018 - 2030 (USD Million)
  • Table 79 South Africa women's health market, by application, 2018 - 2030 (USD Million)
  • Table 80 South Africa women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 81 South Africa women's health market, by age, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia women's health market, by application, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia women's health market, by age, 2018 - 2030 (USD Million)
  • Table 85 UAE women's health market, by application, 2018 - 2030 (USD Million)
  • Table 86 UAE women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 87 UAE women's health market, by age, 2018 - 2030 (USD Million)
  • Table 88 Kuwait women's health market, by application, 2018 - 2030 (USD Million)
  • Table 89 Kuwait women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 90 Kuwait women's health market, by age, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Women's health market: market outlook
  • Fig. 14 Women's health competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Women's health market driver impact
  • Fig. 20 Women's health market restraint impact
  • Fig. 21 Women's health market strategic initiatives analysis
  • Fig. 22 Women's health market: Application movement analysis
  • Fig. 23 Women's health market: Application outlook and key takeaways
  • Fig. 24 Hormonal infertility market estimates and forecast, 2018 - 2030
  • Fig. 25 Contraceptives estimates and forecast, 2018 - 2030
  • Fig. 26 Postmenopausal osteoporosis market estimates and forecast, 2018 - 2030
  • Fig. 27 Endometriosis & uterine fibroids estimates and forecast, 2018 - 2030
  • Fig. 28 Menopause market estimates and forecast, 2018 - 2030
  • Fig. 29 Polycystic ovary syndrome (PCOS) estimates and forecast, 2018 - 2030
  • Fig. 30 Women's health market: Drug movement analysis
  • Fig. 31 Women's health market: Drug outlook and key takeaways
  • Fig. 32 Hormonal Therapies market estimates and forecast, 2018 - 2030
  • Fig. 33 Bone Health Agents market estimates and forecast, 2018 - 2030
  • Fig. 34 Fertility Agents market estimates and forecast, 2018 - 2030
  • Fig. 35 GnRH Modulators estimates and forecast, 2018 - 2030
  • Fig. 36 Pain and Symptom Management market estimates and forecast, 2018 - 2030
  • Fig. 37 Metabolic Agents estimates and forecast, 2018 - 2030
  • Fig. 38 Others estimates and forecast, 2018 - 2030
  • Fig. 39 Women's health Market: Age movement Analysis
  • Fig. 40 Women's health market: Age outlook and key takeaways
  • Fig. 41 50 years and above market estimates and forecasts, 2018 - 2030
  • Fig. 42 Postmenopausal osteoporosis market estimates and forecasts,2018 - 2030
  • Fig. 43 Endometriosis & uterine fibroids market estimates and forecasts,2018 - 2030
  • Fig. 44 Menopause market estimates and forecasts,2018 - 2030
  • Fig. 45 Others market estimates and forecasts,2018 - 2030
  • Fig. 46 Others market estimates and forecasts,2018 - 2030
  • Fig. 47 Global women's health market: Regional movement analysis
  • Fig. 48 Global women's health market: Regional outlook and key takeaways
  • Fig. 49 Global women's health market share and leading players
  • Fig. 50 North America market share and leading players
  • Fig. 51 Europe market share and leading players
  • Fig. 52 Asia Pacific market share and leading players
  • Fig. 53 Latin America market share and leading players
  • Fig. 54 Middle East & Africa market share and leading players
  • Fig. 55 North America: SWOT
  • Fig. 56 Europe SWOT
  • Fig. 57 Asia Pacific SWOT
  • Fig. 58 Latin America SWOT
  • Fig. 59 MEA SWOT
  • Fig. 60 North America, by country
  • Fig. 61 North America
  • Fig. 62 North America market estimates and forecasts, 2018 - 2030
  • Fig. 63 U.S.
  • Fig. 64 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 65 Canada
  • Fig. 66 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 67 Mexico
  • Fig. 68 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 69 Europe
  • Fig. 70 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 71 UK
  • Fig. 72 UK market estimates and forecasts, 2018 - 2030
  • Fig. 73 Germany
  • Fig. 74 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 75 France
  • Fig. 76 France market estimates and forecasts, 2018 - 2030
  • Fig. 77 Italy
  • Fig. 78 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 79 Spain
  • Fig. 80 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 81 Denmark
  • Fig. 82 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 83 Sweden
  • Fig. 84 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 85 Norway
  • Fig. 86 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 87 Asia Pacific
  • Fig. 88 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 89 China
  • Fig. 90 China market estimates and forecasts, 2018 - 2030
  • Fig. 91 Japan
  • Fig. 92 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 93 India
  • Fig. 94 India market estimates and forecasts, 2018 - 2030
  • Fig. 95 Thailand
  • Fig. 96 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 97 South Korea
  • Fig. 98 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 99 Australia
  • Fig. 100 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 101 Latin America
  • Fig. 102 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 103 Brazil
  • Fig. 104 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 105 Argentina
  • Fig. 106 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 107 Middle East and Africa
  • Fig. 108 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 109 South Africa
  • Fig. 110 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 111 Saudi Arabia
  • Fig. 112 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 113 UAE
  • Fig. 114 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 115 Kuwait
  • Fig. 116 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 117 Market share of key market players- Women's health market